The present disclosure provides methods for determining the ploidy status of a chromosome in a gestating fetus from genotypic data measured from a sample of DNA from the mother of the fetus and from the fetus, and from genotypic data from the mother and optionally also from the father. The ploidy state is determined by using a joint distribution model to create a set of expected allele distributions for different possible fetal ploidy states given the parental genotypic data, and comparing the expected allelic distributions to the pattern of measured allelic distributions measured in the mixed sample, and choosing the ploidy state whose expected allelic distribution pattern most closely matches the observed allelic distribution pattern. In an embodiment, the mixed sample of DNA may be preferentially enriched at a plurality of polymorphic loci in a way that minimizes the allelic bias.

A method of predicting therapeutic efficacy of a combined drug is provided. The method of predicting therapeutic efficacy of a combined drug can be useful in efficiently predicting therapeutic efficacy of the combined drug on cells by establishing and learning data through a computer using data on cells, data on individual drugs, and data on reaction between the cells and the individual drugs.

The orthogonal space random walk (OSRW) algorithm is generalized to be the orthogonal space tempering (OST) method via the introduction of the orthogonal space sampling temperature. A double-integration recursion method enables practically efficient and robust OST free energy calculations, augmented by a -dynamics approach. The double-integration OST method performs alchemical free energy simulations, to calculate the free energy difference between benzyl phosphonate and difluorobenzyl phosphonate in aqueous solution, to estimate the solvation free energy of the octanol molecule, and to predict the nontrivial Barnase-Barstar binding affinity change induced by the Barnase N58A mutation. The DI-OST method robustly enables practically efficient free energy predictions, particularly when strongly coupled slow environmental transitions are involved. A classical set of p38 MAP Kinase inhibitors are also employed as a test bed for evaluating relative binding affinity calculation methods. Throughout the molecular dynamics (MD) sampling no human intervention was involved

Systems and methods for displaying gene- and/or protein-related data with respect to chromosome maps at locations identifying relevant positioning of the genes with which the gene- and/or protein related data are associated. Multiple experiments may be plotted onto the display adjacent one or more chromosome maps. Automatic extraction of genomic location, based on accession numbers or other unique identifiers and cross connection with expression data is provided. Statistical assessments of correlations between expression and genome localization may be performed. Zooming capabilities, thumbnail/fullview toggling, browsability and linked data may be included as features of the visualization systems described.

The present invention relates to methods for evaluating the probability that a patient's diagnosis may be treated with a particular clinical regimen or therapy.

The present invention relates to methods for evaluating the probability that a patient's diagnosis may be treated with a particular clinical regimen or therapy.

Systems and methods described herein include those for the continual modification of intestinal microbes. Described herein are systems including sampling devices, analysis devices, computational devices and user interface devices as well as methods for the use of such devices in combination.

Methods and apparatus for predicting responsiveness to immune therapy in lung cancer. The method includes the steps of: identifying a first population of known responders and a second population of known non-responders; processing imaging data for the first and second populations using quantitative textural analysis (QTA); generating, for each member of both populations, quantitative metrics using the QTA; performing logistical regression on the quantitative metrics for both populations to yield a predictive signature expressed in the form of Y=Mx+B where x comprises mean pixel density; performing QTA on a lung cancer scan for a subsequent patient; comparing the predictive signature to one or more relevant metrics associated with the subsequent patient; and predicting responsiveness to immune therapy for the subsequent patient based on the comparison.

A method of controlling relaxation equipment is a method of controlling relaxation equipment capable of changing a biological value of a user. The method includes: obtaining a user model including a transition in biological value within a period from a start time to an end time of a program being viewed by the user; obtaining a first biological value of the user viewing the program; and controlling the relaxation equipment such that the biological value of the user at the end time approximates a second biological value included in the user model, which is a value at the end time, based on the first biological value and the second biological value.

The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting. This invention also relates to compounds and pharmaceutical compositions comprising the identified compounds for the treatment of disease conditions due to viral infections caused by viruses of the Orthomyxoviridae family.